KR100682219B1 - 종양 전이를 저해하는 인터루킨-18 저해물질의 용도 - Google Patents

종양 전이를 저해하는 인터루킨-18 저해물질의 용도 Download PDF

Info

Publication number
KR100682219B1
KR100682219B1 KR1020027000682A KR20027000682A KR100682219B1 KR 100682219 B1 KR100682219 B1 KR 100682219B1 KR 1020027000682 A KR1020027000682 A KR 1020027000682A KR 20027000682 A KR20027000682 A KR 20027000682A KR 100682219 B1 KR100682219 B1 KR 100682219B1
Authority
KR
South Korea
Prior art keywords
cells
hse
adhesion
tnf
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020027000682A
Other languages
English (en)
Korean (ko)
Other versions
KR20020027493A (ko
Inventor
차알스 디나렐로
Original Assignee
아레스 트레이딩 에스.아.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아레스 트레이딩 에스.아. filed Critical 아레스 트레이딩 에스.아.
Publication of KR20020027493A publication Critical patent/KR20020027493A/ko
Application granted granted Critical
Publication of KR100682219B1 publication Critical patent/KR100682219B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020027000682A 1999-07-22 2000-07-17 종양 전이를 저해하는 인터루킨-18 저해물질의 용도 Expired - Lifetime KR100682219B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL13104799A IL131047A0 (en) 1999-07-22 1999-07-22 Use of il-18 inhibitors
IL131047 1999-07-22

Publications (2)

Publication Number Publication Date
KR20020027493A KR20020027493A (ko) 2002-04-13
KR100682219B1 true KR100682219B1 (ko) 2007-02-12

Family

ID=11073044

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027000682A Expired - Lifetime KR100682219B1 (ko) 1999-07-22 2000-07-17 종양 전이를 저해하는 인터루킨-18 저해물질의 용도

Country Status (31)

Country Link
US (1) US7741276B2 (cg-RX-API-DMAC7.html)
EP (1) EP1206274B1 (cg-RX-API-DMAC7.html)
JP (1) JP4827352B2 (cg-RX-API-DMAC7.html)
KR (1) KR100682219B1 (cg-RX-API-DMAC7.html)
CN (1) CN1173736C (cg-RX-API-DMAC7.html)
AR (1) AR024907A1 (cg-RX-API-DMAC7.html)
AT (1) ATE363288T1 (cg-RX-API-DMAC7.html)
AU (1) AU782478B2 (cg-RX-API-DMAC7.html)
BG (1) BG65800B1 (cg-RX-API-DMAC7.html)
BR (1) BR0012675A (cg-RX-API-DMAC7.html)
CA (1) CA2380216C (cg-RX-API-DMAC7.html)
CY (1) CY1107932T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ302114B6 (cg-RX-API-DMAC7.html)
DE (2) DE60035049T2 (cg-RX-API-DMAC7.html)
DK (1) DK1206274T3 (cg-RX-API-DMAC7.html)
EA (1) EA005419B1 (cg-RX-API-DMAC7.html)
EE (1) EE04838B1 (cg-RX-API-DMAC7.html)
ES (1) ES2186596T3 (cg-RX-API-DMAC7.html)
HK (1) HK1048248B (cg-RX-API-DMAC7.html)
HU (1) HU228780B1 (cg-RX-API-DMAC7.html)
IL (2) IL131047A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02000838A (cg-RX-API-DMAC7.html)
NO (1) NO329827B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ516535A (cg-RX-API-DMAC7.html)
PL (1) PL202477B1 (cg-RX-API-DMAC7.html)
PT (1) PT1206274E (cg-RX-API-DMAC7.html)
SK (1) SK287522B6 (cg-RX-API-DMAC7.html)
TR (1) TR200200169T2 (cg-RX-API-DMAC7.html)
UA (1) UA73745C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001007480A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200200390B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK12942002A3 (sk) 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
AU2002211744B8 (en) 2000-10-11 2008-03-20 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
BR0210904A (pt) * 2001-05-16 2005-08-16 Yeda Res & Dev Uso de inibidores de il-18 para o tratamento ou prevenção de sepse
RU2225720C1 (ru) * 2002-08-12 2004-03-20 Научно-исследовательский институт онкологии Томского научного центра СО РАМН Средство, повышающее противоопухолевую и антиметастатическую активность циклофосфана
BR0315155A (pt) * 2002-10-08 2005-08-16 Ares Trading Sa Uso de citocina capaz de ligar il-18bp e de inibir a atividade de uma segunda citocina
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
CA2609060C (en) 2005-06-03 2014-07-15 Urs Weber Production of recombinant il-18 binding protein
PT1891088E (pt) 2005-06-10 2011-12-19 Ares Trading Sa Processo para a purificação da proteína de ligação il-18
CL2008002153A1 (es) 2007-07-24 2009-06-05 Amgen Inc Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
US9812033B2 (en) * 2013-03-06 2017-11-07 Venkatesh R. Chari Tactile graphic display
CA3259975A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
EP4646433A1 (en) 2023-01-06 2025-11-12 Lassen Therapeutics, Inc. Anti-il-18bp antibodies
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ299210A (en) * 1992-09-02 2000-08-25 Isis Pharmaceuticals Inc Treating diseases characterised by changes in intercellular adhesion molecules using coding sequences hybridizable with those encoding proteins involved in synthesis of such molecules
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
SK122199A3 (en) * 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use

Also Published As

Publication number Publication date
BRPI0012675B1 (pt) 2001-02-01
HU228780B1 (en) 2013-05-28
BRPI0012675B8 (cg-RX-API-DMAC7.html) 2021-05-25
DE60035049T2 (de) 2007-09-27
IL147675A (en) 2009-05-04
AR024907A1 (es) 2002-10-30
KR20020027493A (ko) 2002-04-13
HUP0202107A2 (en) 2002-10-28
EA200200189A1 (ru) 2002-12-26
CZ2002195A3 (cs) 2002-06-12
CN1364086A (zh) 2002-08-14
NO20020153L (no) 2002-03-11
DK1206274T3 (da) 2007-08-13
JP4827352B2 (ja) 2011-11-30
NO329827B1 (no) 2011-01-03
PT1206274E (pt) 2007-07-06
NZ516535A (en) 2004-04-30
CN1173736C (zh) 2004-11-03
TR200200169T2 (tr) 2002-06-21
HK1048248A1 (en) 2003-03-28
HK1048248B (zh) 2005-04-22
JP2003505472A (ja) 2003-02-12
UA73745C2 (en) 2005-09-15
US20080003216A1 (en) 2008-01-03
ES2186596T3 (es) 2007-11-16
SK287522B6 (sk) 2011-01-04
PL202477B1 (pl) 2009-06-30
CZ302114B6 (cs) 2010-10-20
AU782478B2 (en) 2005-08-04
WO2001007480A2 (en) 2001-02-01
BG65800B1 (bg) 2009-12-31
EE04838B1 (et) 2007-06-15
ATE363288T1 (de) 2007-06-15
HUP0202107A3 (en) 2005-01-28
EP1206274A2 (en) 2002-05-22
AU5843200A (en) 2001-02-13
BG106311A (en) 2002-08-30
EP1206274B1 (en) 2007-05-30
CY1107932T1 (el) 2013-09-04
EE200200032A (et) 2003-02-17
IL131047A0 (en) 2001-01-28
SK882002A3 (en) 2002-07-02
MXPA02000838A (es) 2002-07-30
CA2380216A1 (en) 2001-02-01
CA2380216C (en) 2012-01-31
NO20020153D0 (no) 2002-01-11
EA005419B1 (ru) 2005-02-24
DE60035049D1 (de) 2007-07-12
ES2186596T1 (es) 2003-05-16
BR0012675A (pt) 2002-04-09
ZA200200390B (en) 2003-04-30
PL353732A1 (en) 2003-12-01
WO2001007480A3 (en) 2001-05-10
US7741276B2 (en) 2010-06-22
DE1206274T1 (de) 2002-11-14

Similar Documents

Publication Publication Date Title
US7741276B2 (en) Use of interleukin-18 inhibitors to inhibit tumor metastasis
Li et al. Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells
Yamamura et al. Interferon‐γ–inducing activity of interleukin‐18 in the joint with rheumatoid arthritis
Dinarello Interleukin-18
HRP950052A2 (en) Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels
AU2005277236A1 (en) Methods and compositions for treating allergic inflammation
Yamauchi et al. Cytokine modulation in acute pancreatitis
Jayaraman et al. Enhancement of in vivo cell-mediated immune responses by three distinct cytokines.
EP1466619A2 (en) Method for modulating cell apoptosis
KR20010024549A (ko) Ｔｎｆ 길항제의 패혈증 치료를 위한 약제로서의 용도
JPH0725785A (ja) インターロイキン−６の医薬組成物
CA2231433A1 (en) Method for modulating cell apoptosis
MXPA06006377A (es) Metodos para modular la actividad de citocina y reactivos relacionados.
Wiltrout et al. The Use of Cytokine Knockout Mice in Cancer Research
Jiang Increased core temperature during febrile disease modulates cytokine expression, enhances host defense, and improves survival in bacterial infection
DJAAFAR Effects of IL-15 and its specific inhibitor, the mutant IL-15/FCγ2Aprotein, on bone turnover: new factors in osteo-inmmune context

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20020117

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20030122

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20050705

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060831

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20061230

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20070206

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20070206

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20100204

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20101228

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20120203

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20130117

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20130117

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20140120

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20140120

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20150120

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20150120

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20160119

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20160119

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20170119

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20170119

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20180119

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20180119

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20190117

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20190117

Start annual number: 13

End annual number: 13

PC1801 Expiration of term

Termination date: 20210117

Termination category: Expiration of duration